Drug Profile
IDP 113
Alternative Names: IDP-113Latest Information Update: 18 Jul 2018
Price :
$50
*
At a glance
- Originator Dow Pharmaceutical Sciences
- Developer Bausch Health Companies
- Class Antifungals; Small molecules; Triazoles
- Mechanism of Action 14-alpha demethylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Tinea capitis
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 30 Aug 2010 Phase II development is ongoing in USA